Quang D Pham1, David P Wilson, Matthew G Law, Anthony D Kelleher, Lei Zhang. 1. aThe Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia bDepartment for Disease Control and Prevention, The Pasteur Institute, Ho Chi Minh City, Vietnam.
Abstract
OBJECTIVES: Our aim was to review the global disparities of transmitted HIV drug resistance (TDR) in antiretroviral-naive MSM, people who inject drugs (PWID) and heterosexual populations in both high-income and low/middle-income countries. DESIGN/ METHODS: We undertook a systematic review of the peer-reviewed English literature on TDR (1999-2013). Random-effects meta-analyses were performed to pool TDR prevalence and compare the odds of TDR across at-risk groups. RESULTS: A total of 212 studies were included in this review. Areas with greatest TDR prevalence were North America (MSM: 13.7%, PWID: 9.1%, heterosexuals: 10.5%); followed by western Europe (MSM: 11.0%, PWID: 5.7%, heterosexuals: 6.9%) and South America (MSM: 8.3%, PWID: 13.5%, heterosexuals: 7.5%). Our data indicated disproportionately high TDR burdens in MSM in Oceania (Australia 15.5%), eastern Europe/central Asia (10.2%) and east Asia (7.8%). TDR epidemics have stabilized in high-income countries, with a higher prevalence (range 10.9-12.6%) in MSM than in PWID (5.2-8.3%) and heterosexuals (6.4-9.0%) over 1999-2013. In low/middle-income countries, TDR prevalence in all at-risk groups in 2009-2013 almost doubled than that in 2004-2008 (MSM: 7.8 vs. 4.2%, P = 0.011; heterosexuals: 4.1 vs. 2.6%, P < 0.001; PWID: 4.8 vs. 2.4%, P = 0.265, respectively). The risk of TDR infection was significantly greater in MSM than that in heterosexuals and PWID. We observed increasing trends of resistance to non-nucleoside reverse transcriptase and protease inhibitors among MSM. CONCLUSION: TDR prevalence is stabilizing in high-income countries, but increasing in low/middle-income countries. This is likely due to the low, but increasing, coverage of antiretroviral therapy in these settings. Transmission of TDR is most prevalent among MSM worldwide.
OBJECTIVES: Our aim was to review the global disparities of transmitted HIV drug resistance (TDR) in antiretroviral-naive MSM, people who inject drugs (PWID) and heterosexual populations in both high-income and low/middle-income countries. DESIGN/ METHODS: We undertook a systematic review of the peer-reviewed English literature on TDR (1999-2013). Random-effects meta-analyses were performed to pool TDR prevalence and compare the odds of TDR across at-risk groups. RESULTS: A total of 212 studies were included in this review. Areas with greatest TDR prevalence were North America (MSM: 13.7%, PWID: 9.1%, heterosexuals: 10.5%); followed by western Europe (MSM: 11.0%, PWID: 5.7%, heterosexuals: 6.9%) and South America (MSM: 8.3%, PWID: 13.5%, heterosexuals: 7.5%). Our data indicated disproportionately high TDR burdens in MSM in Oceania (Australia 15.5%), eastern Europe/central Asia (10.2%) and east Asia (7.8%). TDR epidemics have stabilized in high-income countries, with a higher prevalence (range 10.9-12.6%) in MSM than in PWID (5.2-8.3%) and heterosexuals (6.4-9.0%) over 1999-2013. In low/middle-income countries, TDR prevalence in all at-risk groups in 2009-2013 almost doubled than that in 2004-2008 (MSM: 7.8 vs. 4.2%, P = 0.011; heterosexuals: 4.1 vs. 2.6%, P < 0.001; PWID: 4.8 vs. 2.4%, P = 0.265, respectively). The risk of TDR infection was significantly greater in MSM than that in heterosexuals and PWID. We observed increasing trends of resistance to non-nucleoside reverse transcriptase and protease inhibitors among MSM. CONCLUSION: TDR prevalence is stabilizing in high-income countries, but increasing in low/middle-income countries. This is likely due to the low, but increasing, coverage of antiretroviral therapy in these settings. Transmission of TDR is most prevalent among MSM worldwide.
Authors: Harshana S De Silva Feelixge; Daniel Stone; Harlan L Pietz; Pavitra Roychoudhury; Alex L Greninger; Joshua T Schiffer; Martine Aubert; Keith R Jerome Journal: Antiviral Res Date: 2015-12-22 Impact factor: 5.970
Authors: Seble G Kassaye; Zehava Grossman; Maya Balamane; Betsy Johnston-White; Chenglong Liu; Princy Kumar; Mary Young; Michael C Sneller; Irini Sereti; Robin Dewar; Catherine Rehm; William Meyer; Robert Shafer; David Katzenstein; Frank Maldarelli Journal: Clin Infect Dis Date: 2016-06-15 Impact factor: 9.079
Authors: Trevor A Crowell; Gustavo H Kijak; Eric Sanders-Buell; Anne Marie O'Sullivan; Afoke Kokogho; Zahra F Parker; John Lawlor; Christina S Polyak; Sylvia Adebajo; Rebecca G Nowak; Stefan D Baral; Merlin L Robb; Manhattan E Charurat; Julie A Ake; Nicaise Ndembi; Sodsai Tovanabutra Journal: Antivir Ther Date: 2019
Authors: Karla D Passalacqua; Marie-Eve Charbonneau; Nicholas J Donato; Hollis D Showalter; Duxin Sun; Bo Wen; Miao He; Hanshi Sun; Mary X D O'Riordan; Christiane E Wobus Journal: Antimicrob Agents Chemother Date: 2016-06-20 Impact factor: 5.191
Authors: Theppharit Panichsillapakit; Davey M Smith; Joel O Wertheim; Douglas D Richman; Susan J Little; Sanjay R Mehta Journal: J Acquir Immune Defic Syndr Date: 2016-02-01 Impact factor: 3.731
Authors: Fred Kyeyune; Richard M Gibson; Immaculate Nankya; Colin Venner; Samar Metha; Juliet Akao; Emmanuel Ndashimye; Cissy M Kityo; Robert A Salata; Peter Mugyenyi; Eric J Arts; Miguel E Quiñones-Mateu Journal: Antimicrob Agents Chemother Date: 2016-05-23 Impact factor: 5.191